Hologic, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOLX research report →
Companywww.hologic.com
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- CEO
- Paul Malenchini
- IPO
- 1990
- Employees
- 7,063
- HQ
- Marlborough, MA, US
Price Chart
Valuation
- Market Cap
- $16.97B
- P/E
- 31.36
- P/S
- 4.11
- P/B
- 3.25
- EV/EBITDA
- 17.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 52.82%
- Op Margin
- 17.49%
- Net Margin
- 13.18%
- ROE
- 11.01%
- ROIC
- 7.18%
Growth & Income
- Revenue
- $4.10B · 1.74%
- Net Income
- $565.70M · -28.35%
- EPS
- $2.50 · -25.37%
- Op Income
- $714.30M
- FCF YoY
- -19.64%
Performance & Tape
- 52W High
- $76.07
- 52W Low
- $51.90
- 50D MA
- $75.29
- 200D MA
- $71.28
- Beta
- 0.70
- Avg Volume
- 4.49M
Get TickerSpark's AI analysis on HOLX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 7, 26 | Verstreken Jan | other | 31,409 |
| Apr 7, 26 | Verstreken Jan | sell | 12,490 |
| Apr 7, 26 | Verstreken Jan | sell | 13,971 |
| Apr 7, 26 | Verstreken Jan | sell | 15,387 |
| Apr 7, 26 | Verstreken Jan | sell | 29,002 |
| Apr 7, 26 | Verstreken Jan | sell | 12,509 |
| Apr 7, 26 | Verstreken Jan | sell | 17,831 |
| Apr 7, 26 | Verstreken Jan | sell | 19,327 |
| Apr 7, 26 | Verstreken Jan | sell | 20,056 |
| Apr 7, 26 | Verstreken Jan | sell | 18,698 |
Our HOLX Coverage
We haven't published any research on HOLX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HOLX Report →